Shares of NantKwest (NASDAQ:NK) have received a consensus rating of “Hold” from the six research firms that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $3.50.
Several equities research analysts recently weighed in on the stock. BidaskClub raised shares of NantKwest from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Zacks Investment Research cut shares of NantKwest from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Raymond James Financial reiterated a “hold” rating on shares of NantKwest in a report on Monday, December 11th.
Several institutional investors have recently modified their holdings of the company. State Street Corp raised its position in NantKwest by 52.9% in the 2nd quarter. State Street Corp now owns 341,007 shares of the biotechnology company’s stock valued at $2,589,000 after purchasing an additional 117,946 shares during the last quarter. Vident Investment Advisory LLC grew its stake in NantKwest by 40.3% in the 4th quarter. Vident Investment Advisory LLC now owns 262,014 shares of the biotechnology company’s stock valued at $1,176,000 after acquiring an additional 75,201 shares during the last quarter. Renaissance Technologies LLC grew its stake in NantKwest by 23.2% in the 4th quarter. Renaissance Technologies LLC now owns 232,900 shares of the biotechnology company’s stock valued at $1,046,000 after acquiring an additional 43,800 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of NantKwest by 116.7% during the 4th quarter. Deutsche Bank AG now owns 67,847 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 36,542 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in shares of NantKwest by 58.1% during the 2nd quarter. California State Teachers Retirement System now owns 54,154 shares of the biotechnology company’s stock worth $411,000 after purchasing an additional 19,900 shares during the last quarter. Institutional investors and hedge funds own 15.89% of the company’s stock.
Shares of NantKwest stock traded up $0.08 on Wednesday, reaching $3.69. The company had a trading volume of 46,092 shares, compared to its average volume of 242,127. The company has a market capitalization of $285.30, a price-to-earnings ratio of -2.48 and a beta of 2.83. NantKwest has a 52-week low of $2.71 and a 52-week high of $8.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.35 and a current ratio of 6.35.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/09/nantkwest-nk-given-average-recommendation-of-hold-by-brokerages.html.
NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Receive News & Ratings for NantKwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest and related companies with MarketBeat.com's FREE daily email newsletter.